阿培利司联合氟维司群或来曲唑治疗 PIK3CA 突变的 HR+/HER2- 晚期乳腺癌患者具有持续获益，且各亚组获益一致。
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
出版信息
Oncologist. 2022 Mar 28;27(Suppl 1):S13-S14. doi: 10.1093/oncolo/oyac011.
Abstract
Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, -mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.
摘要
根据 II 期 BYLieve 试验所有 3 个队列的更新结果，阿培利司联合内分泌治疗为 HR 阳性、HER2 阴性、-突变的晚期乳腺癌患者提供持续的治疗获益。
相似文献
1
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.阿培利司联合氟维司群或来曲唑治疗 PIK3CA 突变的 HR+/HER2- 晚期乳腺癌患者具有持续获益，且各亚组获益一致。
Oncologist. 2022 Mar 28;27(Suppl 1):S13-S14. doi: 10.1093/oncolo/oyac011.
2
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
3
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.阿培利司联合氟维司群对比 HR+/HER2-、PIK3CA 突变型乳腺癌患者真实世界标准治疗的疗效。
Oncologist. 2021 Jul;26(7):e1133-e1142. doi: 10.1002/onco.13804. Epub 2021 May 13.
4
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.阿培利司联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性、PIK3CA 突变的晚期乳腺癌：SOLAR-1 的最终总生存结果。
Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25.
5
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?阿培利司联合氟维司群治疗美国 PIK3CA 突变、HR+/HER2-晚期乳腺癌是否具有成本效益？
Clin Drug Investig. 2023 Dec;43(12):939-948. doi: 10.1007/s40261-023-01325-z. Epub 2023 Nov 17.
6
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.美国食品药品监督管理局批准概要：Alpelisib 联合氟维司群用于治疗激素受体阳性、人表皮生长因子受体 2 阴性、PIK3CA 突变的、晚期或转移性乳腺癌患者。
Clin Cancer Res. 2021 Apr 1;27(7):1842-1849. doi: 10.1158/1078-0432.CCR-20-3652. Epub 2020 Nov 9.
7
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.阿培利司联合来曲唑在 CDK4/6 抑制剂治疗后对 PIK3CA 突变的 HR+/HER2-晚期乳腺癌有疗效。
Oncologist. 2021 Feb;26 Suppl 2(Suppl 2):S15-S16. doi: 10.1002/onco.13662. Epub 2021 Jan 5.
8
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ -mutated breast cancer.一项在 HER2 突变型乳腺癌中进行的 alpelisib+曲妥珠单抗+氟维司群与曲妥珠单抗+化疗的 III 期临床试验。
Future Oncol. 2022 Jun;18(19):2339-2349. doi: 10.2217/fon-2022-0045. Epub 2022 Apr 25.
9
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.阿培利司联合氟维司群治疗 PI3KCA 突变型和野生型雌激素受体阳性晚期乳腺癌：一项 Ib 期临床试验。
JAMA Oncol. 2019 Feb 1;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475. Epub 2019 Feb 14.
10
Potential for Long-Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA-Mutated Advanced Breast Cancer.阿培利司联合氟维司群治疗 HR+/PIK3CA 突变型晚期乳腺癌具有长期疾病控制潜力，涵盖了不同亚组患者。
Oncologist. 2021 Jul;26 Suppl 3(Suppl 3):S11-S12. doi: 10.1002/onco.13873. Epub 2021 Jun 26.
引用本文的文献
1
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.超越激素受体：液体活检工具揭示管腔样转移性乳腺癌的新临床意义并助力治疗决策
Breast. 2025 Feb;79:103859. doi: 10.1016/j.breast.2024.103859. Epub 2024 Dec 12.
2
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in -Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights.PLK1抑制剂Onvansertib增强阿培利司在PIK3CA突变的对哌柏西利和内分泌治疗耐药的HR阳性乳腺癌中的疗效：临床前见解
Cancers (Basel). 2024 Sep 25;16(19):3259. doi: 10.3390/cancers16193259.
3
Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations.乳腺癌 PIK3CA 热点突变的基因组剖析和突变特异性靶点发现。
BMC Genomics. 2024 May 27;25(1):519. doi: 10.1186/s12864-024-10368-1.
4
Genomic dissection and mutation-specific target discovery for breast cancer hotspot mutations.乳腺癌热点突变的基因组剖析与突变特异性靶点发现
bioRxiv. 2024 Jan 4:2024.01.03.574067. doi: 10.1101/2024.01.03.574067.
5
Breast cancer: an up-to-date review and future perspectives.乳腺癌：最新综述及未来展望。
Cancer Commun (Lond). 2022 Oct;42(10):913-936. doi: 10.1002/cac2.12358. Epub 2022 Sep 8.
Zotero 插件